Effects of black hoof medicinal mushroom, phellinus linteus (Agaricomycetes), polysaccharide extract in streptozotocin-induced diabetic rats

International Journal of Medicinal Mushrooms

Volumn 18, Issue 4, 2016, Pages 301-311

  Yamaç, Mustafa ^a   Zeytinoğlu, Melih ^b   Şentürk, Hakan ^a   Kartkaya, Kazim ^a   Kanbak, Göngör ^a   Bayramoğlu, Gökhan ^c   Oğlakci, Ayşegül ^a   Van Griensven, Leo J L D ^d  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b ANADOLU UNIVERSITY   (Turkey)

^c ARTVIN CORUH UNIVERSITY   (Turkey)

^d WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Antidiabetic activity; Medicinal mushrooms; Phellinus linteus; Polysaccharide; Rat

Indexed keywords

CASPASE 3; CATHEPSIN B; CATHEPSIN L; FUNGAL EXTRACT; GLUCOSE; PHELLINUS LINTEUS EXTRACT; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; INSULIN; PLANT EXTRACT; POLYSACCHARIDE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD BIOCHEMISTRY; COLORIMETRY; CONTROLLED STUDY; DNA FRAGMENTATION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; NONHUMAN; OXIDATIVE STRESS; PHELLINUS LINTEUS; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BASIDIOMYCETES; CHEMICALLY INDUCED; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODEL; DRUG EFFECTS; FRUITING BODY; HUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET; SECRETION (PROCESS); SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BASIDIOMYCOTA; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FRUITING BODIES, FUNGAL; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; PLANT EXTRACTS; POLYSACCHARIDES; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 84978731870     PISSN: 15219437     EISSN: 19404344     Source Type: Journal    
DOI: 10.1615/IntJMedMushrooms.v18.i4.30     Document Type: Article

References (31)

1. IDF Diabetes Atlas Seventh Edition [monograph on the Internet]. Brussels: International Diabetes Federation; 2013 [cited 2016 June 17]. Available from: http://www.diabetesatlas.org/.
2. Robertson RP, Harmon J, Tran PO, Poitout V. β-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53(Suppl 1):S119–24.
3. Chwieralski CE, Welte T, Bühling F. Cathepsin-regulated apoptosis. Apoptosis. 2006;11(2):143–9.
4. O’Brien MA, Kirby R. Apoptosis: a review of pro-apop-totic and anti-apoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care. 2008;18(6):572–85.
5. Chang ST, Wasser SP. The role of culinary-medicinal mushrooms on human welfare with pyramid model for human health. Int. J. Med. Mushrooms. 2012;14(2):95–134.
6. Wasser SP. Medicinal mushroom science: history, current status, future trends, and unsolved problems. Int. J. Med. Mushrooms. 2010;12(1):1–16.
7. Vitak TY, Wasser SP, Nevo E, Sybirna NO. The effect of the medicinal mushrooms Agaricus brasiliensis and Ganoderma lucidum (higher Basidiomycetes) on the erythron system in normal and streptozotocin-induced diabetic rats. Int. J. Med. Mushrooms. 2015;17(3): 276–83.
8. Sarikurkcu C, Tepe B, Yamac M. Evaluation of the antioxidant activity of four edible mushrooms from the Central Anatolia, Eskisehir-Turkey: Lactarius deterrimus, Suillus collitinus, Boletus edulis, Xerocomus chrysenteron. Biores Technol. 2008;99:6651–5.
9. Wei S, Van Griensven LJLD. Pro- and antioxidative properties of medicinal mushroom extracts. Int. J. Med. Mushrooms. 2008;10(4):315–24.
10. De Silva DD, Rapior S, Hyde KD, Bahkali AH. Medicinal mushrooms in prevention and control of diabetes mellitus. Fungal Divers. 2012;56:1–29.
11. Lo HC, Wasser SP. Medicinal mushrooms for glycemic control in diabetes mellitus: current status, future perspectives, and unsolved problems. Int. J. Med. Mushrooms. 2011;13(5):401–26.
12. Zhu T, Kim SH, Chen CY. A medicinal mushroom: Phellinus linteus. Curr Med Chem. 2008;15(13):1330–5.
13. Kozarski MS, Klaus A, Niksic M, Jakovljevic D, Helsper JPFG, Van Griensven LJLD. Antioxidative and immu-nomodulating activities of polysaccharide extracts of the medicinal mushrooms Agaricus bisporus, Agaricus brasiliensis, Ganoderma lucidum and Phellinus linteus. Food Chem. 2011;129:1667–75.
14. Kim SH, Song YS, Kim SK, Kim BC, Lim CJ, Park EH. Anti-inflammatory and related pharmacological activities of the n-BuOH subfraction of mushroom Phellinus linteus. J Ethnopharmacol. 2004;93:141–6.
15. Kim OH, Yang BK, Hur NI, Das S, Yun JW, Choi YS, Song CH. Hypoglycemic effects of mycelia produced from submerged culture of Phellinus linteus (Berk. et Curt.) Teng (Aphyllophoromycetidae) in streptozotocin-induced diabetic rats. Int. J. Med. Mushrooms. 2001;3:21–6.
16. Kim OH, Yang BK, Jeong SC, Park JB, Cho SP, Das S, Yun JW, Song CH. Production of a hypoglycemic, extracellular polysaccharide from the submerged culture of the mushroom, Phellinus linteus. Biotechnol Lett. 2001;23:513–7.
17. Zovein A, Flowers-Ziegler J, Thamotharan S, Shin D, Sankar R, Nguyen K, Gambhir S, Devaskar SU. Postnatal hypoxic-ischemic brain injury alters mechanisms mediating neuronal glucose transport. Am J Physiol Regul Integr Comp Physiol. 2004;286(2):R273–R282.
18. Ichihara K, Haneda T, Onodera S, Abiko Y. Inhibition of ischemia-induced subcellular redistribution of lysosomal enzymes in the perfused rat heart by the calcium entry blocker, diltiazem. J Pharmacol Exp Ther. 1987;242:1109–13.
19. Kirschke H, Wood L, Reisen F. Activity of lysosomal cysteine proteinase during differentiation of rat skeletal muscle. Biochem J. 1983;214:871–7.
20. Atroshi F, Rizzo A, Biese I, Veijalainen P, Saloniemi H, Sankari S, Andersson K. Fumonisin B1-induced DNA damage in rat liver and spleen: effects of pretreatment with coenzyme Q10, L-carnitine, α-tocopherol and selenium. Pharmacol Res. 1999;40(6):459–67.
21. Maciel RM, Costa MM, Martins DB, França RT, Schmatz R, Graça DL, Duarte MM, Danesi CC, Mazzanti CM, Schetinger MRC, Paim FC, Palma HE, Abdala FH, Stefanello N, Zimpel CK, Felin DV, Lopes ST. Antioxidant and anti-inflammatory effects of quercetin in functional and morphological alterations in streptozotocin-induced diabetic rats. Res Vet Sci. 2013;95(2):389–97.
22. Yamac M, Kanbak G, Zeytinoglu M, Bayramoglu G, Senturk H, Uyanoglu M. Hypoglycemic effect of Lentinus strigosus (Schwein.) Fr. crude exopolysaccha-ride in streptozotocin-induced diabetic rats. J. Med. Food. 2008;11(3):513–7.
23. Kim DH, Yang BK, Jeong SC, Hur NJ, Das S, Yun JW, Choi JW, Lee YS, Song CH. A preliminary study on the hypoglycemic effect of the exo-polymers produced by five different medicinal mushrooms. J Microbiol Biotechnol. 2001;11(1):167–71.
24. Lee YS, Kang YH, Jung JY, Lee S, Ohuchi K, Shin KH, Kang IJ, Park JH, Shin HK, Lim SS. Protein glycation inhibitors from the fruiting body of Phellinus linteus. Biol Pharm Bull. 2008;31(10):1968–72.
25. Jang JS, Lee JS, Lee JH, Kwon DS, Lee KE, Lee SY, Hong HK. Hispidin produced from Phellinus linteus protects pancreatic beta-cells from damage by hydrogen peroxide. Arch Pharm Res. 2010;33(6):853–861.
26. Lee YS, Kang IJ, Won MH, Lee JY, Kim JK, Lim SS. Inhibiton of protein tyrosine phosphatase 1beta by his-pidine derivatives isolated from the fruiting body of Phellinus linteus. Nat Prod Comm. 2010;5(12):1927–1930.
27. Silva D. Medicinal mushroom Phellinus linteus as an alternative cancer therapy. Exp Ther Med. 2010;1(3):407–11.
28. Choi YH, Huh MK, Ryu CH, Choi BT, Jeong YK. Induction of apoptotic cell death by mycelium extracts of Phellinus linteus in human neuroblastoma cells. Int J Mol Med. 2004;14(2):227–32.
29. Guo J, Zhu T, Collins L, Xiao ZX, Kim SH, Chen CY. Modulation of lung cancer growth arrest and apoptosis by Phellinus linteus. Mol Carcinog. 2007;46(2):144–54.
30. Ben-Ari Z, Mor E, Azarov D, Sulkes J, Tor R, Cheporko Y, Hochhauser E, Pappo O. Cathepsin B inactivation attenuates the apoptotic injury induced by ischemia/reperfusion of mouse liver. Apoptosis. 2005;10(6):1261–9.
31. Cailhier JF, Sirois I, Laplante P, Lepage S, Raymond MA, Brassard N, Prat A, Iozzo RV, Pshezhetsky AV, Hébert MJ. Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. J Biol Chem. 2008;283(40):27220–27229.